Evidence map›Paper›PMID 42890580›Full record

ArticleFrontiers in oncology2026

Pretreatment body mass index as a prognostic factor for clinical course and survival in primary surgically treated oral squamous cell carcinoma - a retrospective study.

Eike Floegel, Leonard Simon Brandenburg, Janek Aaron Arias Romero, Kirstin Vach, Marc Christian Metzger, Rainer Schmelzeisen, Jonas Wüster

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eike FloegelDepartment of Oral and Maxillofacial Surgery, University Medical Center Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Baden-Württembergm, Freiburg, Germany.
Leonard Simon BrandenburgDepartment of Oral and Maxillofacial Surgery, University Medical Center Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Baden-Württembergm, Freiburg, Germany.
Janek Aaron Arias RomeroDepartment of Oral and Maxillofacial Surgery, University Medical Center Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Baden-Württembergm, Freiburg, Germany.
Kirstin VachInstitute of Medical Biometry and Statistics, University Medical Center Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Baden-Württemberg, Freiburg, Germany.
Marc Christian MetzgerDepartment of Oral and Maxillofacial Surgery, University Medical Center Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Baden-Württembergm, Freiburg, Germany.
Rainer SchmelzeisenDepartment of Oral and Maxillofacial Surgery, University Medical Center Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Baden-Württembergm, Freiburg, Germany.
Jonas WüsterDepartment of Oral and Maxillofacial Surgery, University Medical Center Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Baden-Württembergm, Freiburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In oral squamous cell carcinoma (OSCC), body mass index (BMI) is an available but imperfect marker of nutritional reserve. Evidence on pretreatment BMI in surgery-based European OSCC cohorts remains limited, especially regarding perioperative outcomes. This study evaluated associations of pretreatment BMI with overall survival (OS), recurrence-free survival (RFS), and perioperative outcomes after curative-intent R0 resection. Methods: This retrospective single-center cohort included adult patients with previously untreated primary OSCC, available pretreatment BMI, and curative-intent R0 surgery between 2014 and 2023. BMI was assessed continuously and by World Health Organization (WHO) categories. OS and RFS were analyzed using multivariable Cox regression adjusted for age, sex, pathological T category, nodal status, microvascular free-flap reconstruction, and diabetes mellitus. Perioperative outcomes included red blood cell (RBC) transfusion, RBC units transfused, percutaneous endoscopic gastrostomy (PEG) placement, and intensive care unit (ICU) and hospital length of stay. Results: A total of 274 patients with available pretreatment BMI were included; 116 deaths occurred. Five-year OS ranged from 31.4% in patients classified as underweight to 82.0% in patients with obesity. Higher BMI was associated with lower mortality (HR per 1 kg/m² 0.95, 95% CI 0.91-0.99; p = 0.013), and obesity was associated with improved OS compared with normal weight (HR 0.50, 95% CI 0.26-0.96; p = 0.037). BMI was not significantly associated with RFS after adjustment (HR per 1 kg/m² 0.97, 95% CI 0.93-1.00; p = 0.080). Higher BMI was associated with fewer perioperative RBC transfusions (any transfusion: OR 0.91, 95% CI 0.84-0.98; p = 0.012; number of units: OR 0.89, 95% CI 0.82-0.95; p = 0.001). BMI was not independently associated with PEG placement or hospital length of stay; ICU findings depended on BMI modeling. Discussion: Higher pretreatment BMI was associated with better OS and lower perioperative RBC transfusion requirements, whereas associations with RFS and most other perioperative outcomes were not significant after adjustment. Given the retrospective design and limitations of BMI as a body-composition marker, these findings should be interpreted cautiously. Pretreatment BMI may help identify low-BMI patients warranting early supportive-care assessment.

Indexed as

body mass indexfree-flap reconstructionoral squamous cell carcinomaoverall survivalrecurrence-free survivalred blood cell transfusion

Identifiers

PMID42890580
PMCPMC13671965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.